A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors

  1. Saura, C.
  2. Roda, D.
  3. Roselló, S.
  4. Oliveira, M.
  5. Macarulla, T.
  6. Pérez-Fidalgo, J.A.
  7. Morales-Barrera, R.
  8. Sanchis-García, J.M.
  9. Musib, L.
  10. Budha, N.
  11. Zhu, J.
  12. Nannini, M.
  13. Chan, W.Y.
  14. Sanabria Bohórquez, S.M.
  15. Meng, R.D.
  16. Lin, K.
  17. Yan, Y.
  18. Patel, P.
  19. Baselga, J.
  20. Tabernero, J.
  21. Cervantes, A.
Aldizkaria:
Cancer Discovery

ISSN: 2159-8290,  2159-8274

Argitalpen urtea: 2017

Alea: 7

Zenbakia: 1

Orrialdeak: 102-113

Mota: Artikulua

DOI: 10.1158/2159-8290.CD-16-0512 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus